OrthoLogic Rehab Divestiture Will Fund Chrysalin Osteobiologics Development

OrthoLogic is planning to divest its $60 mil. orthopedic rehabilitation device business and use the proceeds for further development of the osteobiologic product Chrysalin, and to expand the company's remaining fracture healing and spinal repair business, including possible acquisitions.